Pyrrolizidine alkaloids (PAs) are plant metabolites present in some botanical preparations, with especially 1,2-unsaturated PAs being of concern because they are genotoxic carcinogens. This study presents an overview of tumour data on PAs and points of departure (PODs) derived from them, corroborating that the BMDL 10 for lasiocarpine represents a conservative POD for risk assessment. A risk assessment using this BMDL 10 and mean levels of PAs reported in literature for (herbal) teas, indicates that consumption of one cup of tea a day would result in MOE values lower than 10 000 for several types of (herbal) teas, indicating a priority for risk management for these products A refined risk assessment using interim relative potency (REP) factors showed that based on the mean PA levels, 7(54%) of 13 types of (herbal) teas and 1 (14%) of 7 types of plant food supplements (PFS) resulted in MOE values lower than 10 000, indicating a priority for risk management also for these products in particular. This includes both preparations containing PA-producing and non-PA-producing plants. Our study provides insight in the current state-of-the art and limitations in the risk assessment of PA-containing food products, especially (herbal) teas and PFS, indicating that PAs in food presents a field of interest for current and future risk management.
Introduction
Pyrrolizidine alkaloids (PAs) are naturally occurring chemicals which are produced by a large number of plants (Griffin et al., 2013) . To date, more than 660 PAs and PA N-oxides have been identified from an estimated 6000 plants (Bodi et al., 2014) . Especially 1, 2-unsaturated PAs are hepatotoxic and considered as genotoxic carcinogens, thus posing a potential risk to human health (Mori et al., 1985) . The 1, 2-unsaturated PAs can be subdivided by the type of esterification in monoesters, open chained diesters and cyclic diesters (Fig. 1 ). In addition, cyclic diester PAs with an azacyclooctenone, instead of a 1, 2-dehydropyrrolizidine ring system, form a special class (Fig. 1) .
Botanical preparations such as (herbal) teas and plant food supplements (PFS) are widely used around the world. However, these preparations have recently been shown to frequently contain toxic PAs (Bodi et al., 2014; IPCS, 1988; Mulder et al., 2015) . Bodi et al. (2014) together with the Federal Institute for Risk Assessment (BfR) in Germany who also reported part of the data (BfR, 2013) , analysed seven types of herbal drugs (41 samples) and 11 types of (herbal) teas (282 samples) all supposedly to be derived from non-PA-producing plants. The results showed that (herbal) teas can contain significant levels of PAs of up to 5647 mg/kg dry material, while in herbal drugs the total PA level could reach up to 3099 mg/kg (Bodi et al., 2014) . The PAs present in the (herbal) teas and PFS were suggested to originate from contamination with PAcontaining weeds during harvesting. Mulder et al. (2015) analysed four types of PFS (110 samples) which were derived from non-PA-producing plants, pollen-based supplements (29 samples) and two types of PFS (39 samples) which were derived from PAproducing plants. These authors also analysed eight types of (herbal) teas (169 samples) which were derived from non-PAproducing plants and five types of (herbal) teas (12 samples) derived from PA-producing plants. For (herbal) teas and PFS which were derived from non-PA-producing plants, the level of PAs amounted up to 4805 and 8488 mg/kg in dry material, respectively. For (herbal) teas and PFS which were derived from PA-producing plants, the levels of PAs amounted up to 31 101 mg/kg in specific teas (as dry material) and to 2 410 275 mg/kg in PFS (Note: In March 2017 the PA levels reported for 13 herbal tea samples in the study of Mulder et al. (2015) have been revised. Consequently, EFSA will publish a revised version of the original scientific report on the internet (Patrick P.J. Mulder, patrick. mulder@wur.nl). The revised levels have been taken into account in the calculations). These data showed that the highest values were obtained for (herbal) teas and PFS produced from PAproducing plants, but that PAs are also present in samples produced from non-PA-producing plants. Recently, upon a request form the European Commission, the European Food Safety Authority (EFSA) published a dietary exposure assessment reporting estimates for chronic and acute exposure to PAs using the PA data collected and available in the EFSA Chemical Occurrence database (EFSA, 2016a) . The data on tea and herbal infusions were submitted by several data providers including five national authorities, and consisted of data provided by tea producers and traders organised in Tea & Herbal Infusions Europe (THIE), as well as data provided by Bodi et al. (2014) and Mulder et al. (2015) . EFSA expressed the PA levels per liter of tea infusion as consumed dividing the level in mg/ kg dry material by 75 assuming 100% extraction of the PAs present in 2 g of tea into 150 mL of boiling water. The 95th percentile values amounted up to 773 mg/kg for individual dry (herbal) tea samples and 55 459 mg/kg in PFS, including data from material from PAproducing plants (EFSA, 2016a,b) .
In the studies reported by Bodi et al. (2014) , Mulder et al. (2015) and EFSA (2016a), no risk assessment was presented for the PA levels detected. Given that 1,2-unsaturated PAs are considered to be genotoxic and carcinogenic, the risk assessment can best be done by applying the Margin of Exposure (MOE) approach (EFSA, 2011) . To calculate the MOE for a particular compound preferably a BMDL 10 from a carcinogenicity study (benchmark dose lower confidence limit for 10% extra risk on tumour formation above background levels) is normally used as a point of departure (POD). So far, suitable experimental data to derive such BMDL 10 values have only been reported for two PAs, lasiocarpine and riddelliine (NTP, 1978; NTP, 2003) . For lasiocarpine EFSA calculated a BMDL 10 of 0.07 mg/kg bw/day based on data for induction of liver haemangiosarcomas in male rats and used this as POD for comparison with the estimated dietary exposure resulting from the presence of PAs in retail honey (EFSA, 2011) . EFSA indicated that the carcinogenic potency of most PAs present in honey is likely to be lower than that of lasiocarpine and that a risk characterisation using the BMDL 10 for lasiocarpine is considered a conservative approach. This is based on the consideration that lasiocarpine is amongst the most toxic of the PAs that have been tested based on the LD 50 upon a single intraperitoneal (i.p.) dose (COT, 2008) , and the fact that toxicity may be associated with the carcinogenicity. This assumption is in line with the fact that for riddelliine a BMDL 10 of 0.18 mg/kg bw/day was calculated based on the incidence of liver haemangiosarcomas in female rats (EFSA, 2011; NTP, 2003) . In addition to lasiocarpine and riddelliine, other PAs, including monocrotaline, clivorine, senkirkine and symphytine, (Fig. 1) , have been shown to cause tumours in animal bioassays (Hirono et al., 1979; Kuhara et al., 1980; Shumaker et al., 1976) . Monocrotaline has been classified as a Group 2 B carcinogen (possibly carcinogenic to humans) by the International Agency for Research on Cancer (IARC), while senkirkine and symphytine have been classified as Group 3 (not classifiable as to its carcinogenicity to humans (IARC, 1976; IARC, 1983; IARC, 2002) . For these PAs available tumour data are not suitable for dose response modelling and definition of BMDL 10 values, but their data could still be used to provide a better estimate of how conservative the use of the BMDL 10 of lasiocarpine for risk assessment on 1,2-unsaturated PAs would be. PODs for calculating the MOE in situations where the data do not facilitate dose-response modelling to obtain a BMDL 10 are the T25 and/or T10 values, representing the dose levels resulting in 25 or 10% tumour incidence above back ground levels after lifetime exposure (BfR, 2009; EFSA, 2005) . In their opinion on a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic EFSA already indicated that in cases where the data would be unsuitable for deriving a BMDL 10 , use of the T25 is recommended (EFSA, 2005) . EFSA also indicated that when using the T25 for calculation of the MOE a value of 25 000 instead of 10 000 could be used to judge if the MOE indicates a priority for risk management (EFSA, 2005) . To facilitate comparison to other genotoxic carcinogens BfR derived an MOE based risk assessment for glycidol and its esters, using the T10 calculated from the T25 by linear extrapolation (multiplying the T25 by 10/25) as an alternative for the BMDL 10 for calculating MOE values (BfR, 2009) .
In 2013, the BfR presented an initial risk assessment on PAs in (herbal) teas for children and adults using several consumption scenarios (BfR, 2013) . In their report, BfR considered the toxic potency of all the PAs as equal when calculating MOE values. It was concluded that it is improbable that short term intake (up to 14 days) poses a health risk for adults and children but that there is a concern for people who frequently drink large quantities of the (herbal) teas. This risk assessment was based on tea samples from the German market and the BMDL 10 for lasiocarpine, using several consumption scenarios. BfR indicated that the intake estimates used were likely either overstated or underestimated as they included average group PA content values for all types of teas, while tea consumption reported by consumers and used for the intake estimates is also likely to include other tea varieties that tend to have either lower or higher PA contents. Indeed, it is necessary to consider the fact that some types of (herbal) tea infusion may contain large amounts of PAs, as a relevant food safety issue. This also holds true for PFS.
As already indicated above the toxic potency of different PAs may be different. In view of this, Merz and Schrenk (2016) recently have proposed interim relative potency (REP) factors for PAs, that describe the relative (toxic) potency of each congener compared with the most toxic congener(s) (Merz and Schrenk, 2016) . Based on available literature data on in vitro cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents (LD50), REP factors were defined for the most relevant structural types of PAs, 1.0 for cyclic di-esters and open-chained di-esters with 7S configuration, 0.3 for mono-esters with 7S configuration, 0.1 for open-chained diesters with 7R configuration and 0.01 for mono-esters with 7R configuration (Merz and Schrenk, 2016) . It should be noticed that these interim REP values do not take the relative potency of PAs for tumour formation into account. Furthermore, a risk assessment based on the PA levels in (herbal) teas or PFS, taking the interim REP factors into account, has so far not been performed. Given this situation the aims of the present study were i) to analyse the literature available on PA induced tumour incidences, to define PODs for PAs other than lasiocarpine and to further evaluate the use of the BMDL 10 of lasiocarpine for risk assessment of 1,2-unsaturated PAs and ii) to present a risk assessment on the use of (herbal) teas and PFS containing PAs using the new data presented by Bodi et al. (2014) , Mulder et al. (2015) and EFSA (2016a) taking into account the interim REP factors.
Materials and methods

Literature search
To obtain the required data on PA-induced tumour incidences, a literature search was performed using Google Scholar by combining the search terms: 'pyrrolizidine alkaloids', 'carcinogenic' and 'rats' or 'mice'. References that met all the search criteria were collected. From these studies, the essential information, such as number of animals, species, gender, dose, tumour data and experimental time, was extracted for further evaluation. Based on the carcinogenicity data, potential PODs were defined as described hereafter.
PODs definition for risk assessment
Using the BMD method, the lower confidence limit of the benchmark dose (BMD) giving a 10% extra cancer incidence (BMDL 10 ) was determined as a preferred POD for the MOE approach. BMD modelling was performed using all models for dichotomous data of the Environmental Protection Agency (EPA)'s Benchmark Dose Software (BMDS) version 2.6 applying default settings. All models that met the requirements for acceptance (Pvalue > 0.05 and BMD 10 /BMDL 10 <10) were considered for the determination of BMDL 10 values choosing the lowest BMDL 10 value for further assessment. To calculate BMDL 10 values, data should preferably refer to three experimental doses administrated to rats or mice, with at least 50 animals per group and a two-year experimental period (Edler et al., 2014) . However, in some experiments, the study was terminated before completion of a two-year (104 weeks) period and the actual treatment period was even shorter. For these studies an adjustment of the dose level was performed using the formula: dose Â (weeks of treatment/104) Â (weeks of observation/104) (ECHA, 2008) , resulting in the dose levels used for deriving the POD. For example for the data on clivorine, the experimental dose (5 mg/kg bw/day given for 340 days (¼ 49 weeks), with experiment termination at 480 days (¼ 69 weeks) was adjusted by multiplying the dose by (49/104) Â (69/104), giving a dose of 1.56 mg/kg bw/day.
In case the data are insufficient for the calculation of a BMDL 10 , EFSA has recommended the T25 as an alternative point for MOE calculation. T25 values are calculated by dividing the extra risk (% incidence in the dose group minus % incidence in the control group) by the non-affected fraction in the control population (100 minus background response in %), and converting the dose level causing this tumour incidence to the dose level causing 25% extra tumour incidence by linear extrapolation. For example, if the incidence in the control group was 5/50 (10%) and in the 30 mg/kg bw/day group (30/50 (60%)), the extra risk is [(60e10)/(100e10)]/100 ¼ 55.6% and the T25 ¼ 25/55.6 Â 30 mg/kg bw/day ¼ 13.5 mg/kg bw/day (Benford et al., 2010) . T10 values were calculated from the T25 by linear extrapolation, multiplying by 10/25. It is of interest to note that one could argue that statistically a T10 would compare to a BMD 10 rather than to a BMDL 10 but at the current state of the art the T25 with a MOE cut off value of 25 000 and the T10 with a MOE cut off value of 10 000 (also applied when using the BMDL 10 ) are used as PODs when a BMDL 10 is not available.
Estimated daily intake (EDI) calculation
A number of different data sets were used for estimating exposure including those reported by Bodi et al. (2014) , Mulder et al. (2015) and EFSA (2016a). The mean and maximum values of total PA content for different types of (herbal) teas or PFS obtained from Bodi et al. (2014) are summarised in Supplementary Tables S5  and S9 . Instead of maximum PA levels, the EFSA report gives the 95th percentile values (EFSA, 2016a) . These data together with the mean values of total PA contents for (herbal) teas and PFS are summarised in Supplementary Tables S6 and S10 . Only the data reported by Mulder et al. (2015) were presented at the level of detail needed for 'adjustment' of the PA levels by REP factors. The mean and maximum total PA content for different (herbal) teas or PFS obtained from Mulder et al. (2015) are summarised in Supplementary Tables S7 and S11 and the corresponding data adjusted by REP factors and are presented in Supplementary Tables S8 and S12. The total PA levels that were used in this study were the ones based on the lower bound approach, meaning that only quantified levels were taken into account and that nondetected PAs were ignored. To perform the risk assessments, the daily PA intake resulting from use of the (herbal) teas was estimated assuming daily consumption of the amount of PAs present in 2 g tea, corresponding to one cup of tea, as described before (BfR, 2013) . Due to the wide range of the recommended daily intake between PFS products (COT, 2003) , it is difficult to achieve a consensus estimate on the general PFS daily intake. In this study, the daily PA intake resulting from use of PFS was estimated by assuming a dose of 200 mg PFS. This dose reflects the low end of intake of botanical supplements (Van Den Berg et al., 2011) . The estimated daily intakes (EDIs) were calculated using a default body weight of 70 kg for an adult as proposed by EFSA (EFSA, 2012).
Calculation of the Margin of Exposure
The MOE was calculated by dividing the selected POD (BMDL 10 or T10 as indicated) by the EDI. To evaluate the possible health risk and priority for risk management actions an MOE value of 10 000 was applied. This value of 10 000 includes a factor of 100, consisting of a factor of 10 for possible inter-species differences, and a factor of 10 for differences between human individuals. Furthermore it includes an additional factor of 10 to account for inter-individual human variability in cell cycle control and DNA repair and a factor 10 because the MOE is based on the BMDL 10 which is not a no effect level (EFSA, 2005 ). An MOE value of 10 000 or higher, based on animal cancer bioassay data, is considered to be a low concern from a public health standpoint, while a value lower than 10 000 might raise a potential concern for human health (EFSA, 2005) . When using the T25 for calculation of the MOE a value of 25 000 instead of 10 000 should be used to judge if the MOE indicates a safety concern (EFSA, 2005) . As proposed by the BfR a value of 10 000 could be considered when using a T10 to facilitate comparison to the BMDL 10 (BfR, 2009). Table 1 provides an overview of the carcinogenicity data of PAs as present in the literature, describing the incidence of liver haemangiosarcomas for lasiocarpine and riddelliine, pulmonary adenocarcinomas for monocrotaline, liver neoplastic nodules for clivorine, liver cell adenomas for senkirkine and hemangioendothelial sarcoma of the liver for symphytine, in all cases observed in rats. Only the data for lasiocarpine, and riddelliine appeared suitable for BMD modelling, as was also concluded by EFSA (EFSA, 2011) . The results of a BMD analysis of these data confirmed the BMDL 10 values previously reported by EFSA, of 0.07 and 0.18 mg/ kg bw/day for lasiocarpine and riddelliine, respectively, based on the data for induction of liver haemangiosarcoma in male and female rats (Table 2) . Based on the experimental doses, the duration of the studies and tumour incidences, T25 and T10 values for induction of the different tumour types were calculated for monocrotaline, clivorine, senkirkine and symphytine (Supplementary Tables S1eS4). Table 2 presents an overview of these values listing the lowest BMDL 10 and T10 values for the tumour types that can be used as a preferred POD for the further assessment. For monocrotaline, the T10 value was 1.5 mg/kg bw/day based on a study using subcutaneous (s.c.) administration of monocrotaline inducing pulmonary adenocarcinoma in male rats (Shumaker et al., 1976) . The T10 value for clivorine was 0.31 mg/kg bw/day based on a rat study in which clivorine was administered in drinking water, inducing an increased incidence of liver neoplastic nodules in the liver in male and female rats (Kuhara et al., 1980) . The T10 values were 2.4 mg/kg bw/day for senkirkine and 4.0 mg/kg bw/day for symphytine, based on the incidence of liver cell adenomas and liver haemangioendothelial sarcoma, respectively, in male rats exposed via i.p. injection (Hirono et al., 1979) . T10 values derived for lasiocarpine and riddelliine amounted to 0.16 and 0.09 mg/kg bw/day and were thus somewhat different from the BMDL 10 values derived from the same data. Based on comparison of the BMDL 10 and T10 values shown in Table 2 , it can be concluded that the BMDL 10 of 0.07 mg/kg bw/day for lasiocarpine, appears to be the lowest POD of all values obtained. This value is 3e60-fold lower than the PODs obtained for related 1, 2-unsaturated PAs (Table 2 ). This indicates that lasiocarpine is the most toxic PA compared to those for which tumour data are available and that therefore a risk characterisation based on the BMDL 10 for lasiocarpine can indeed be considered a conservative approach (EFSA, 2011). However, given the fact that for several PAs the POD seems to be more than ten-fold higher than the BMDL 10 for lasiocarpine, it should be kept in mind that, depending on the nature of the PAs actually present, use of the BMDL 10 for lasiocarpine may result in MOE values that may be too low.
Results
Carcinogenicity data and PODs for PAs
Estimated daily intakes (EDIs) and risk assessment of PAs from consumption of (herbal) teas
Based on the mean and maximum PA levels reported by Bodi Table S5 ), the EDI and MOE values for a total of 11 types of (herbal) teas (with at least 9 samples per type of tea) were calculated assuming daily consumption of one cup of tea (using 2 g dry tea). Fig. 2 presents the resulting MOE values for the different types of (herbal) teas based on the BMDL 10 for lasiocarpine. The MOE values ranged from 430 to around 47 500 upon consumption of one cup of (herbal) tea per day. Overall, the MOE values vary significantly among the different types of (herbal) teas. Depending on the use of mean or maximum PA levels, the types of tea with MOE values below 10 000, amount to four (36%) and nine (82%) of the 11 types of (herbal) teas, respectively. More specifically, based on the mean PA level, MOE values lower than 10 000 were found for chamomile, black, rooibos and melissa teas ( Fig. 2A) . In addition to those teas, the MOE values of mixed herbal, peppermint, green, fennel and nettle teas were below 10 000 when taking the maximum PA levels into account (Fig. 2B) . It is of interest to note that all (herbal) teas were derived from non-PA-producing plants. Fig. 3 presents MOE values calculated by using the mean and 95th percentile of total PA values based on the type of (herbal) teas that were reported by EFSA (2016a), including the data reported by Bodi et al. (2014) and Mulder et al. (2015) . The EDI and MOE values were calculated by assuming consumption of one cup of tea per day (2 g dry weight) and are presented in the Supplementary Table S6 . Based on the mean PA levels, most types of teas have MOE values higher than 10 000 except peppermint and rooibos tea (Fig. 3A) . When considering the 95th percentile PA levels, in addition to peppermint and rooibos tea, another four types of tea, including tea and herbs, black, green and chamomile teas, were found to result in MOE values below 10 000 (Fig. 3B) . Again, all of these are from non-PA-producing plants. Table 2 Lowest BMDL 10 and T10 values as derived from data on the incidence of tumours in rats exposed to lasiocarpine, riddelliine, monocrotaline, clivorine, senkirkine and symphytine. For a full overview of all data and PODs see Supplementary materials Tables S1eS4.
Compound
Species Fig. 2 . The MOE values for 11 different types of herbal teas obtained for daily consumption of one cup of tea per day using A) mean, B) maximum PA levels reported by Bodi et al. (2014) . The number of teas analysed in each category is given in brackets. # PA content < LOQ. The BMDL 10 for lasiocarpine is used as POD.
Estimated daily intakes (EDIs) and risk assessment of PAs from consumption of (herbal) teas, taking relative potencies into account
The data reported by Mulder et al. (2015) (see note above on the recent revision of the report) also include information on the individual PAs detected, which is essential when taking the different potencies of the PAs into account by applying REP factors. The individual PA levels reported by Mulder et al. (2015) were recalculated using the interim REP factors, reported by Merz and Schrenk (2016) , to adjust the mean and maximum total PA levels and to calculate the EDI values for 13 types of (herbal) teas in relative potency assuming consumption of one cup of tea. These data without and with taking the REP factors into account are presented in the Supplementary Tables S7 and S8, respectively. The MOE values thus obtained, either with or without taking the REP factors into account, are presented in Fig. 4 . After REP factor correction, the MOE values ranged from 460 to around 445 000 upon consumption of one cup of (herbal) tea per day. Based on the mean and maximum PA levels and with taking the REP factors into account, the types of teas with MOE values below 10 000, amounted to 7 (54%) and 8 (62%) out of a total of 13 types of (herbal) teas, respectively. More specifically, based on the mean PA levels and REP correction, MOE values less than 10 000 were found for peppermint, rooibos, black, green, mixed herbal, borago and coltsfoot tea (Fig. 4A) . When considering maximum PA levels, also camomile flower resulted in MOE values below 10 000 (Fig. 4B) . Of these teas, chamomile flowers, peppermint, rooibos, black, green and mixed herbs are derived from non-PA-producing plants, whereas borago and coltsfoot are derived from PA-producing plants. It is of interest to note that the MOE values for chamomile flowers, peppermint, rooibos, black, green and mixed herbs increase by only about 1e2 fold after applying REP factors. This limited effect is due to the fact that the major PAs in these teas were senecionine, retrorsine and seneciphylline for which the interim REP factors are 1.0. In contrast, for teas derived from PA containing plants such as borago, gromwell, eupatorium and lungwort, the MOE values increased by 30e100 fold after applying REP factors (Fig. 4) , due to the fact that the major PAs in these preparations were intermedine and lycopsamine, for which the proposed REP factors are 0.01 (Merz and Schrenk, 2016) .
Estimated daily intakes (EDIs) and risk assessment of PAs from consumption of plant food supplements
The EDI and MOE values for seven types of PFS for which PA levels were reported by Bodi et al. (2014) are presented in the Supplementary Table S9 . The different types of PFS with MOE values lower or higher than 10 000 upon daily consumption of 200 mg PFS per day are presented in Fig. 5 . Overall, the MOE values vary considerably among the types of PFS, ranging from 7900 to around 17 500 000. Based on the mean or maximum PA levels reported, none and one (14%) of a total of seven types of PFS resulted in an MOE value below 10 000, respectively (Fig. 5) . Based on the maximum PA levels, the MOE values of PFS containing anise that were derived from non-PA-producing plants were lower than 10 000 (Fig. 5B) . Fig. 6 presents MOE values calculated by using mean and the 95th percentile of total PA levels of PFS that were reported by EFSA (2016a). The EDI and MOE values were calculated by assuming consumption of 200 mg PFS per day and presented in the Supplementary Table S10. According to either the mean or the 95th percentile PA values, the plant extract formula supplements resulted in an MOE value below 10 000 (Fig. 6) .
Estimated daily intakes (EDIs) and safety assessment of PAs from consumption of plant food supplements taking relative potencies into account
The EDI and MOE values, without and with REP factor correction for seven types of PFS reported by Mulder et al. (2015) are presented in the Supplementary Tables S11 and S12. The MOE values upon daily consumption of 200 mg PFS per day are presented in Fig. 7 . Overall, and taking the relative potencies into account, the MOE values vary substantially among the types of PFS, ranging from 1000 to around 983 000. Based on the mean and maximum PA levels, when taking the relative potencies into account, only the supplements prepared from PA-plant extract formula resulted in an MOE value below 10 000, accounting for one (14%) of the seven types of PFS investigated (Fig. 7) . It is of interest to note that only a small proportion of the PFS analysed contained lasciocarpine: two PA-plant extract formulas out of 18 (11%), three out of 75 samples (4%) of non-PA-producing plants extract formulas and none of the 29 pollen-based PFS. Supplements containing special fatty acids, derived from PA-producing plants did not contain measurable amounts of PAs due to the fact that in the production process the PAs are effectively removed by refinement of the oil. These products therefore comply with legislation in the Netherlands that states that preparations made from PA-containing plants shall not contain more than 1 mg/kg PAs (Warenwetbesluit kruidenpreparaten 2001) (Supplementary materials Tables S11 and S12) . Notably, the MOE values of pollen-based supplements, plant extract formula made of non-PA-producing plant material, valerian, St John's wort or PAproducing plant extract material increased after applying REP factors by about 6-, 4-, 1-, 10-and 65-fold, respectively. This can be ascribed to the fact that the major PAs present in these PFS were lycopsamine, intermedine and echimidine , which were reported to have REP factors of 0.01, 0.01 and 0.1, respectively (Merz and Schrenk, 2016) .
Discussion
In the present study, first a literature review on tumour data on PAs was performed to obtain a better insight in PODs available for risk assessment of PAs and the extent to which the BMDL 10 of lasiocarpine currently used presents a worst case POD. Data on lasiocarpine and riddelliine were available and suitable for doseresponse modelling, providing the BMDL 10 values reported previously by EFSA of 0.07 and 0.18 mg/kg bw/day, respectively (EFSA, 2011) . In addition, tumour data for monocrotaline, clivorine, senkirkine and symphytine were retrieved that were unsuitable for a BMD modelling but allowed derivation of a T25 and T10. In a carcinogenicity study of monocrotaline in male rats, there were treatment-related increases in a number of tumours, principally liver cell carcinomas and pulmonary adenocarcinomas (Shumaker , 1976) . The T10 value for liver cell carcinomas of 3.0 mg/kg bw/ day was higher than the T10 for pulmonary adenocarcinomas (1.5 mg/kg bw/day). The latter was thus selected as the preferred POD for monocrotaline. Clivorine induced an increased incidence of haemangioendothelial sarcomas and neoplastic nodules in the liver of rats (Kuhara et al., 1980) . Although the T10 value of liver hemangioendothelial sarcoma was higher than that derived for liver neoplastic nodules (0.96 vs 0.31 mg/kg bw/day), liver neoplastic nodules, being non-malignant tumours, may be less suitable for the risk assessment thus leaving the T10 of 0.96 mg/ kg bw/day as the POD for clivorine. Senkirkine increased the incidence of liver cell adenomas with a T10 of 2.4 mg/kg bw/day and symphytine induced liver haemangioendothelial sarcoma, a type of malignant tumour, with a lower T10 value than that for liver cell adenomas (4.0 mg/kg bw/day vs 12 mg/kg bw/day). All these tumour data appeared inadequate for dose response modelling, because only one level of dosing was included in the studies. The T25 has been suggested by EFSA as an alternative POD in case a BMDL 10 cannot be calculated (EFSA, 2005) and was recently used for glycidol and its esters (EFSA, 2016b) . For these same compounds BfR used the T10 as an alternative to make an MOE based risk assessment, because it better allows a comparison to the BMDL 10 than the T25 (BfR, 2009). Our results showed that the T10 values of monocrotaline, clivorine, senkirkine and symphytine were 21-, 4-, 34-and 60-fold higher, respectively, than the BMDL 10 value of 0.07 mg/kg bw/day for lasiocarpine (Table 2 ). For comparison, T10 values for lasiocarpine and riddelliine were also calculated by using the data presented in Table 1 . The T10 values amounted to 0.16 and 0.09 mg/kg bw/day, respectively, and were thus somewhat different from the BMDL 10 values derived from the same data (Table 2) . However these values are still in line with the conclusion that the BMDL 10 for lasiocarpine of 0.07 mg/kg bw/day is the lowest POD and thus seems a conservative estimate when applied for other PAs. Given the consideration that ultimately most 1,2-unsaturated PAs lead to the same type of tumour, namely angiosarcomas, and produce the same type of reactive metabolite, a 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) analogue, the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COT) agreed that the BMDL 10 of lasiocarpine, the most potent PA, would be an appropriate basis for the MOE approach for risk assessment of PAs (COT, 2008) . Also EFSA considered lasiocarpine to be the most toxic of the PAs that have been investigated.
(EFSA, 2011) and BfR as well used the BMDL 10 of lasiocarpine in their risk assessment of PAs in teas (BfR, 2013) . The literature overview presented here strongly indicates that this approach using the BMDL 10 of 0.07 mg/kg bw/day for risk assessment of combined exposure to 1,2-unsturated PAs is a conservative approach since tumour data available for other PAs so far point at PODs that are higher. It is important to note that some of these PODs were derived from studies where the route of administration was not oral but subcutaneous (s.c.) or intraperitoneal (i.p.) ( Table 1 ). Given that bioavailability by these other routes may be different and perhaps higher than by the oral route, this could provide another reason why the use of the BMDL 10 for lasiocarpine for these other PAs might be a conservative approach. It should be noted, that the cancer studies used were carried out in different laboratories, using different species strains, genders, duration and other circumstances. This should be kept in mind when comparing and using the different PODs' (MacGregor et al., 2015) . Based on PA levels reported by Bodi et al. (2014) , when calculating MOE values based on mean and maximum level of PAs, most types of (herbal) teas resulted in MOE values below 10 000. These results indicate a potential risk for human health, even for (herbal) teas derived from non-PA-containing botanicals. The presence of PAs detected in teas made from non-PA-producing plants has been suggested to be due to (unintentional) contamination with PAcontaining weeds during harvesting, processing or blending of the teas (Bodi et al., 2014; Shimshoni et al., 2015) . Better production and manufacture practices will likely result in a reduction of the PA contamination in the end products. For PFS, based on the mean PA level, only one (14%) of in total seven types of PFS would result in EDI values that give rise to an MOE value below 10 000.
To provide a more refined estimate for PA risk assessment, mean and maximum PA levels as reported by Mulder et al. (2015) were used to investigate the effect of applying recently proposed interim REP factors to obtain refined EDI and MOE estimates. The MOE values obtained without REP factor correction were generally lower than those with REP factor correction, especially for the PFS because they contained as major PAs congeners with REP values of 0.01 and 0.1, while in the teas the major PAs were those with REP values of 1.0, resulting only in a limited effect.
It is important to stress that the risk assessment presented here is a conservative estimate in various aspects. First of all, the method of preparing the hot water extracts of (herbal) teas and PFS to determine the PA levels in the procedure applied by Mulder et al. (2015) is stated to be in accordance with the real situation to make a cup of tea, but it should be noted that the method included grinding the (herbal) teas and (part of the) herbal food supplements with dry ice before extraction. Grinding the tea and PFS material with dry ice and to a small particle size ( 500 mm) can be expected to facilitate extraction as compared to using the intact samples as such, with the latter being more representative of daily practice. Extraction without the grinding step could result in lower extraction efficiency and thus, lower EDI and higher MOE values, reducing the concern. Previous studies on the risks of exposure to alkenylbenzenes from consumption of fennel based teas by Van den Berg et al. (2014) and Raffo et al. (2011) reported that hot water extraction of compounds of concern from comminuted fennel fruits is indeed more efficient than from the whole fruits (Raffo et al., 2011; Van den Berg et al., 2014) . The effect of this processing and extraction process on the actual risk of the (herbal) tea and PFS samples should be investigated in more detail. In addition, the PA levels presented, and thus the calculated MOE values, are based on adding up the levels of all 1,2-unsaturated PAs and using the BMDL 10 value of lasiocarpine. This might also contribute to an overestimation of the risk. The results of the present study show that POD values for other PAs are 3e60-fold higher than the BMDL 10 of lasiocarpine. For this reason, calculated MOEs might overestimate the potential risk for human health. Close analysis of the type of PAs present in the different herbal teas and PFS revealed that in most cases lasiocarpine is not a major PA and in the majority of samples it is even absent. However, for the major PAs present in the samples, PODs were absent hampering a further refinement of the MOE calculation. Whether the BMDL 10 for lasiocarpine is really the most appropriate or rather a too conservative POD for risk assessment remains to be established. Use of REP factors to take the relative potencies into account may be a way forward to. It is of interest to note that the interim REP factors defined by Merz and Schrenk (2016) were based on data from in vitro cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents (LD50), and did not take into account in vivo potencies for tumour formation. Comparison of the T10 values presented in the current study to the BMDL 10 of lasiocarpine, provided REP factors for the relative potency in tumour formation of riddelline, monocrotaline, clivorine, senkirkine and symphytine of0.39, 0.05, 0.23, 0.03, and 0.02 respectively, suggesting there is room for further refinement of the interim REP factors now available. This would likely further increase the MOE values.
Another factor to take into account is that the MOE calculations assume daily use of the teas and PFS during a whole lifetime. Calculation of the MOEs using the EDI values over a lifetime might overestimate the potential risk for human health and may therefore not be realistic. It could be considered that use of the (herbal) teas and PFS for only a few weeks instead of during a whole lifetime may decrease EDI values and increase MOE values by 2e3 orders of magnitude indicating their use would no longer be of concern. On the other hand some consumers may take more than one cup of tea a day and use the respective label for longer periods of time. Moreover, although as much as 28 PAs were monitored in the studies of Bodi et al. (2014) , Mulder et al. (2015) and EFSA (2016a), more PAs could be present in herbal teas and PFS that have eluded detection due to the lack of reference standards, resulting in underestimation of the PA content and consequently overestimation of the MOE values.
Yet another factor of importance to note is that the MOE will vary between different age groups. The present MOE values were calculated for adults while consumption of one cup of tea or 200 mg of PFS by children with a 2e3 fold lower body weight will increase the EDI and decrease MOE values accordingly implying higher instead of lower concerns. The Committee On Toxicology (COT) already concluded that the age group with the highest PA exposure on a body weight basis would be infants (COT, 2008) . In addition, the BfR concluded that there was a risk of health impairment, particularly in children (BfR, 2013) .
With respect to the MOE values obtained for the PFS it is important to note that current EDI and resulting MOE values were based on an assumed daily intake of 200 mg of supplement material per person per day. This amount is at the low end of intake estimates often recommended for botanical supplements on the respective labels (Van Den Berg et al., 2011) . Intake of larger amounts would result in proportional increases of the EDI values and decreases of the MOE values resulting in values below 10 000 if intake is much larger than 200 mg a day for some of these PFS.
Finally, it should be considered that honey may be used by some consumers as a sweetener in their tea. Because honey is a food commodity that may also contain PAs (EFSA, 2011) this may further increase PA exposure upon tea consumption. The average level of contamination of retail honey was calculated for the sum of 8 PAs as 16 mg/kg for the lower bound and 26 mg/kg for the upper bound situation (EFSA, 2011) . Data on what percentage of the tea drinkers would actually use honey as a sweetener are not available. One could estimate that using one spoon of 10 g of honey per cup of tea on average would add between 0.16 and 0.26 mg PAs to a cup of tea, amounting to between 0.00229 and 0.00371 mg PAs/kg bw for a 70 kg person. Using the BMDL 10 of lasiocarpine of 0.07 mg/kg bw/ day this would result in an MOE between 18 900 and 30 600 and not be of concern as such, but in combination with (herbal) tea consumption this could in some cases result in MOEs lower than 10 000.In conclusion, use and also further refinement of REP factors defining the relative potency of PAs for tumour induction seems crucial for a refined MOE based risk assessment of products containing PAs. For (herbal) teas, the PA levels and resulting EDI and MOE values for chamomile flowers, peppermint, rooibos, black, green and mixed herbs, which are tea types derived from non-PAproducing plants, and for borago and coltsfoot teas which are derived from PA-producing plants, confirm the importance of risk management actions especially for consumers with regular daily use. For PFS, plant extract formula which were derived from PAproducing plants might pose a potential risk for human health.
Our study provides additional insight in the current state-of-the art and limitations in risk assessment on PA-containing botanical food products, especially on (herbal) teas and PFS, indicating that PAs in food may present an important field of interest for current and future risk management.
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